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Abstract
Metallothionein (MT) is a small, thiol rich protein released into the extracellular
environment in response to stress. Elevated expression of MT has been linked to many
inflammatory diseases including inflammatory bowel diseases, diabetes, and cancer. In breast
cancer, high expression of MT has been associated with poor patient prognosis. Previous studies
have shown that MT acts as a chemoattractant in lymphocytes, and that UC1MT, a monoclonal
anti-MT antibody, can block this chemotactic response. In addition, it has been shown that both
Cholera toxin and Pertussis toxin, which are known antagonists of G-protein coupled receptors,
can inhibit MT-mediated chemotaxis. Here, I investigate the signaling pathways of MT-mediated
chemotaxis using small molecule inhibitors in cellular models of inflammation and breast cancer.
I also examine the chemotactic potential of MT in mammary tumor cell lines and the ability of
UC1MT to block this chemotactic response. Experiments revealed that MT is chemotactic in
mammary tumor cell lines. I have found that, like in lymphocytes, MT interacts with receptor
CXCR4 in breast cancer models to initiate the chemotactic response. Studies conducted using
MT peptides revealed that MT’s N-terminus is likely involved in the binding of this protein to its
receptor. MT-mediated chemotaxis in both immune cells and breast cancer cell models can be
blocked using CK-666 and U73122, but not with PD98059, which suggests that the Arp2/3
complex and phospholipase C (PLC) are involved in MT’s chemotactic signaling pathways, but
that mitogen activated kinase kinase (MEK) is not. Finally, I found that UC1MT can block MTmediated chemotaxis in mammary tumor cell lines. This suggests that UC1MT may be a useful
therapeutic to inhibit breast cancer metastasis.
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Introduction
Metallothionein: Background and Significance
Metallothionein (MT), is a low molecular weight, thiol-rich protein, that is released by
cells into the extracellular environment as a response to stress 1. MT is highly conserved across
many species, and in mammals there are four isoforms of the protein. MT-1 and MT-2 are
expressed at low levels in almost all cell types throughout an organism, while MT-3 and MT-4
have more tissue specific expression2. The experiments conducted for this study focused on the
MT-1 isoform, which will be referred to as MT from this point forward. Traditionally, MT has
been studied in the intracellular environment and has been shown to play a role in metal
homeostasis by interacting with divalent metal cations such as zinc, copper, cadmium, and
mercury via the thiols present in its structure3. MT forms two metal binding domains, the Cterminal α-domain and the N-terminal β-domain (Figure 1). The α-domain is comprised of
amino acids 31-61 and is capable of binding four divalent metals. The β-domain is comprised of
amino acids 1-30 and can bind three divalent metals 4,5.

Figure 1. Mammalian Metallothionein Structure with Metal Binding Pockets 6
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Even though MT is typically studied in the intracellular environment, it also plays a
significant role in the extracellular environment. It has been shown that MT has many
immunomodulatory effects on lymphocytes7. MT plays a role in CD4+ T cell differentiation, and
CD8+ cytotoxic T cell and dendritic cell function8,9. It has also been shown that MT exposure
synergistically enhances T and B cell proliferation when used in conjunction with Concanavalin
A and Lipopolysaccharide respectively10.
Chemotaxis is defined as directional movement of cells or organisms in response to a
chemical or other stimulus. The Lynes Lab has shown that immune cells migrate chemotactically
towards increasing concentrations of MT and that MT exposure results in an increase in F-actin
levels in cells11. The addition of UC1MT, an anti-MT monoclonal antibody, alters the
immunomodulatory effect of MT12,13. In regard to this study, it is of particular interest that
UC1MT can block MT’s chemotactic effect in Jurkat T cells 11.
G-protein coupled receptors (GPCRs) and their downstream signaling pathways are
commonly involved in the initiation of a chemotactic response (Figure 2) 14. A previous study
done in the Lynes lab suggests that a GPCR may be involved in signaling associated with MTmediated chemotaxis since the chemotactic response to MT is blocked by the presence of either
pertussis toxin or cholera toxin, both of which are known antagonists of GPCR mediated
events11. These findings prompted my interest in investigating the signaling pathways of MTmediated chemotaxis and the potential role of GPCRs in initiating these pathways.
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Figure 2. Schematic of GPCR Signaling Pathways Involved in Chemotaxis 14

Metallothionein and Inflammatory Diseases
MT has been linked to the progression of inflammation associated with disease in many
organ systems. Cancer, neuroinflammatory diseases, inflammatory bowel disease, and diabetes
have all been linked to elevated MT expression15,16.
MT has been found to be upregulated in many neurodegenerative diseases including
Alzheimer’s Disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). In
addition, acute and chronic brain injury has been linked to increased levels of MT due to
neuroinflammation and oxidative stress associated with these conditions 15,17.
Inflammatory Bowel Diseases (IBD) such as Crohn’s Disease and ulcerative colitis are
chronic intestinal inflammatory diseases with unclear origins, however it is thought that genetic
factors, environmental factors, and the gut microbiota contribute to the disease phenotype 18,19.
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Studies have shown that MT expression levels are dysregulated in patients with IBD 20. Similarly,
murine colitis models show upregulation of MTs 21. Experiments conducted in murine Dextran
Sodium Sulphate (DSS)-induced colitis model suggest that UC1MT may be a useful tool as a
preventative and therapeutic treatment for colitis as it reduces cell infiltration of the intestinal
epithelium, which is characteristic of inflammation associated with colitis 22.
Type 1 Diabetes (T1D) is an autoimmune disease characterized by a loss of tolerance to
insulin-producing pancreatic β cells, in which the immune system targets these cells for
destruction. In T1D, pancreatic β cells are completely lost, which results in insulin deficiency
and dysregulation of glucose metabolism23. In a study examining the expression of MT at
different stages of T1D development, it was shown that MT-1 and MT-3 levels were increased in
patients with longstanding T1D compared to patients with early onset of the disease and control
patients24. Experiments conducted in non-obese diabetic mice, a mouse model commonly used
for T1D research, have shown that administration of UC1MT results in a decreased blood
glucose level and decreased insulitis score compared to administration of an isotype control 25,
indicating that UC1MT may have a useful clinical application in the prevention of this disease.

Metallothionein and Cancer
Increased expression of MT has been linked to the manifestation of many different
cancers, including glioblastoma, prostate cancer, ovarian, and breast cancer 26–29. The increased
expression of MT in each of these types of cancer indicate a worse prognosis for the patient 27,30.
MT can inhibit apoptosis and protect cells against radiation and cytotoxic alkylating agents.
Because many chemotherapy agents fall into this category, MT can protect cells, including
cancer cells, from the drugs used to eradicate them 27. This association between increased MT
Messina 10

expression and decreased chemotherapy efficacy highlights a gap in current cancer treatment
protocols, one that can potentially be filled by manipulation of the extracellular pool of MT with
UC1MT.

Metallothionein and Breast Cancer
Breast Cancer represents a significant health risks, with an estimated 266,120 new cases
and accounting for an estimated 40,920 deaths in the United States in 2018 31. With one in eight
women developing the disease in her lifetime, breast cancer is the most common cancer
diagnosed and second leading cause of death in women. While 62% of breast cancer cases
involve only a primary tumor, 31% of cases involved metastases to local lymph nodes, and 6%
of cases involve metastases to distant locations in the body. Once the tumor has extended beyond
its primary location, five-year survival rates for patients drop significantly31. Even with modern
therapeutics, metastasis still poses a significant challenge when treating patients with breast
cancer and serves as an important target for new drug development.
Several studies have shown that inflammation plays a key role in the progression of
breast cancer32–35. Of these studies, the one conducted by Pierce is of particular interest as it
suggests that circulating markers of inflammation, including pro-inflammatory cytokines, might
indicate disease recurrence even without a history of metastasis or the presence of other clinical
indications of cancer32.
In breast cancer, increased expression of MT has been associated with greater tumor
grade30. In addition, high levels of MT in breast cancer have been linked to worse tumor
prognosis, including increased likelihood of local tumor recurrence, shorter disease-free interval,
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and decreased survival36. MT’s role in inflammation and its association with poor prognosis in
breast cancer patients suggests that manipulation of this stress response protein may improve
patient outcomes.
In this study, I will investigate the mechanism by which MT initiates a chemotactic
response in immune cells and thus contributes to the inflammatory environment associated with
many disease phenotypes. I will also examine this phenomenon in mammary tumor cell models
to determine if using UC1MT to manipulate the extracellular pool of MT would be a useful
therapeutic approach to inhibit breast cancer metastasis.
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Materials and Methods
Proteins, Antibodies, and Small Molecule Inhibitors
MT-1 from rabbit liver (Cat# ALX-202-072-0000), CK-666 (Cat# ALX-270-506-M002),
U73122 (Cat# BML-ST391-0005), and PD98059 (Cat# BML-EI360-0005) were obtained from
Enzo Life Sciences. Recombinant human SDF-1α was obtained from Shenandoah (Cat# 100-20).
AMD3100 (Cat# A5602) was obtained from Sigma Life Sciences. Thirteen different MT
peptides [MT1-10 (Cat# 65595-1), MT4-12 (Cat# 65595-2), MT11-20 (Cat# 65595-3), MT16-25 (Cat#
65595-4), MT22-31 (Cat# 58274), MT25-35 (Cat#65595-5), MT31-40 (Cat# 65595-6), MT35-43 (Cat#
65595-7), MT40-49 (Cat# 65595-8), MT46-55 (Cat# 65595-9), MT51-61 (Cat# 65595-10), MTsc1
(Cat# 58242-1), and MTsc2 (Cat# 65595-11)] were designed based on the rabbit MT-1 sequence
(Table 1) as described in Bhandari, 2018 and purchased from AnaSpec. UC1MT, a monoclonal
anti-MT antibody, was obtained from Thermo Fisher Scientific.

Table 1. Rabbit MT-1 and MT Peptide Sequences
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Cell Culture
Jurkat T Cells (ATCC TIB-152), a human T lymphocyte leukemia cell line, were cultured
in RPMI-1640 (Sigma, Cat# 8758) with 1% penicillin/streptomycin (Cellgro, Cat# 30-002-CI),
1mM Sodium Pyruvate (MP Biomedicals, Cat# 1682049), 1mM HEPES Buffer (Corning, Cat#
25-060-Cl), 4mM L-Glutamine (Sigma, Cat# 56-58-9), and 10% heat inactivated Fetal Bovine
Serum (Atlanta Biologicals, Cat# S11550) at 37°C with 5% CO 2. Cells were maintained at a
concentration of between 105 and 106 cells per milliliter by aspirating cells in spent media and
replenishing with fresh media using sterile technique.
MDA-MB-231 (ATCC HTB-26), a triple negative human epithelial breast cancer cell
line, was cultured in high glucose Dulbecco's Modified Eagle Medium (Gibco Life Sciences,
Cat# 11965118) with 1% penicillin/streptomycin, 4mM L-Glutamine, and 10% heat inactivated
Fetal Bovine Serum at 37°C with 5% CO2. Cells were maintained at a concentration of between
105 and 106 cells per milliliter by aspirating cells in spent media and replenishing with fresh
media using sterile technique. Because MDA-MB-231 cells are adherent, a cell scraper
(Fisherbrand, Cat# 08-100-241) was used to dislodge them from the bottom of the flask before
each passage.
419, a murine mammary tumor cell line derived from the MMTV-PyMT mouse model,
was obtained from David Lawrence, PhD (New York State Department of Health Wadsworth
Center, Albany NY) and cultured in high glucose Dulbecco's Modified Eagle Medium with 1%
penicillin/streptomycin and 10% heat inactivated Fetal Bovine Serum at 37°C with 5% CO 2.
Cells were maintained at a concentration of between 10 5 and 106 cells per milliliter by aspirating
cells in spent media and replenishing with fresh media using sterile technique. Because 419 Cells
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are a highly adherent cell line, they were treated with Trypsin-EDTA (Sigma Life Sciences, Cat#
T2601) for five minutes then dislodged using a cell scraper before each passage.

Primary Splenocyte Isolation
C57BL/6J mice were euthanized by CO2 asphyxiation. The spleen was harvested using
sterile dissection technique. A single cell suspension was made using a disposable pestle tissue
grinder. Cell suspension was put through a 40µm pore cell strainer (Fisherbrand, Cat# 22363547)
and washed with 4mL of splenocyte media (RPMI-1640 with 1% penicillin/streptomycin, 1mM
sodium pyruvate, 1mM L-Glutamine, 0.1 mM non-essential amino acids (Gibco, Cat# 01216),
and 10% heat inactivated Fetal Bovine Serum). Cells were washed with 10mL of splenocyte
media then the red blood cells were lysed using sterile Ammonium-Chloride-Potassium Lysis
Buffer (150mM ammonium chloride, 10mM potassium bicarbonate, and 0.1mM Na 2EDTA at
pH 7.2). Cells were washed with 10mL splenocyte media. Splenocytes were resuspended in
10mL fresh media and put through a 40µm pore cell strainer. Cell density and viability were
calculated using a hemocytometer and trypan blue (Sigma Life Sciences, Cat# T8154) exclusion
staining.

Boyden Chamber Assay
The Boyden Chamber Assay was conducted in either the 48 (Neuro Probe, Cat# AP48) or
96 (Neuro Probe, Cat# AP96) well Micro Chemotaxis Chamber. Chemoattractants were diluted
to working concentrations in appropriate media. 25µL of chemoattractant were added to the
bottom wells of the Boyden Chamber. Media alone served as a negative control. Incubation
Messina 15

times and membrane pore size were optimized for each cell line used. For Jurkat T cells,
experiments were conducted in the 48 well chamber using 5µm pore membranes (Neuro Probe,
Cat# PFB5). For primary mouse splenocytes, experiments were conducted in the 48 well
chamber using 3µm pore membranes (Neuro Probe, Cat# PFB3). For MDA-MB-231 cells,
experiments were conducted in the 48 well chamber using 8µm pore membranes (Neuro Probe,
Cat# PFB8) coated with 10µg/mL Fibronectin (Sigma Life Sciences, Cat# F0895) in phosphate
buffered saline (PBS) overnight prior to their use. For 419 cells, MT peptide experiments were
conducted in the 96 well chamber, while all other experiments were conducted in the 48 well
chamber. 3µm pore membranes (Neuro Probe, Cat# PFB3 or PFD3) were used for experiments
using 419 cells. After chamber assembly, 50µl of cells in single cell suspension at 2x10 6
cells/mL were added to the wells of the upper chamber. For experiments involving small
molecule inhibitors, cells were pre-incubated with non-toxic doses of either AMD3100 (Figure
S1), CK-666 (Figure S2), U73122 (Figure S3), or PD98059 (Figure S4). After pre-incubation,
cells were washed and resuspended at 2 million cells/mL to be loaded into the wells of the upper
chamber. Chambers were incubated at 37°C with 5% CO 2 for 3 hours (Jurkat T cells, primary
mouse splenocytes, and 419 cells) or 6 hours (MDA-MB-231 cells). After incubation, chambers
were disassembled, and a cell scraper was used to remove the cells from the top side of the
membrane. Cells on the underside of the membrane were stained using the Hema 3 stain set
(Protocol, Cat# 122-911) and were counted under the light microscope at 10x.

Data Analysis
Data was analyzed using the GraphPad Prism 8 software. Each experiment was analyzed
using ordinary one-way analysis of variance (ANOVA) followed by Tukey’s Multiple
Messina 16

Comparisons Test to determine statistical significance. For each statistical test, ns (no
significance) indicates a p value of greater than 0.05, * indicates a p value of less than or equal to
0.05, ** indicates a p value of less than or equal to 0.01, *** indicates a p value of less than or
equal to 0.001, and **** indicates a p value of less than or equal to 0.0001. There was a
minimum of three replicates for each condition in every experiment and the average of these
values was calculated to be used for analysis. All values are displayed with standard deviation.
Graphs are representative results of three independent experiments.

Messina 17

Results
MT is Chemotactic in Mammary Tumor Cell Lines
Previous research conducted in the Lynes Lab has established that MT acts as a
chemoattractant to lymphocytes11,25. As a result, immune cells migrate towards increasing
concentrations of MT in the body, which contributes to inflammation at sites of high MT
expression. This phenomenon contributes to many inflammatory diseases including
inflammatory bowel disease, diabetes, and many types of cancer15. As mentioned earlier, MT
expression is associated with worse outcomes in cancer patients, including those with breast
cancer27,30. MT expression contributes to inflammation found in the tumor micro environment
which plays a key role in the development of the disease 32–35. While the chemotactic role of MT
in the extracellular environment has been studied extensively in Bhandari, 2018, these studies
did not address the role of MT-mediated chemotaxis in breast cancer cells.
For these experiments, I have used two mammary tumor cell lines as models for breast
cancer. MDA-MB-231is a triple negative human epithelial breast cancer cell line commonly
used in breast cancer research. I selected this cell line to model breast cancer in this project as
triple negative breast cancer is particularly challenging to treat with the current available
therapeutics, so it is important to continue to develop new options for treating this disease
phenotype. 419, a murine mammary tumor cell line derived from MMTV-PyMT mice served as
a second model of mammary tumorigenesis. I have selected this murine cell line to model
mammary tumorigenesis as mice are commonly used animal models in breast cancer research,
and the MMTV-PyMT mouse model, from which this cell line is derived from, develops
particularly aggressive mammary tumors, which are challenging to treat.

Messina 18

In Figure 3, I have conducted experiments to determine if MT is chemotactic in breast
cancer. If MT can induce chemotaxis in these mammary tumor cell lines, this may suggest that
MT plays a role in breast cancer metastasis, thereby resulting in a worse prognosis for the
patient.
Using the Boyden Chamber assay, I was able to examine the effect of MT on both MDAMB-231 cells and 419 cells. For these experiments, either media alone or MT was loaded into
the bottom wells of the chamber. The chamber was then assembled and MDA-MB-231 cells
(Figure 3A) or 419 cells (Figure 3B) were loaded with and without MT into the wells of the
upper chamber. When MT was loaded into the wells of the bottom chamber, there was a
statistically significant increase in the average number of cells migrated per well in both MDAMB-231 cells and 419 cells, however when MT was loaded into the wells of the upper chamber
with the cells, there was no increase in cell migration. These results indicated that MT is in fact
chemotactic in MDA-MB-231 cells and 419 cells. Because MT is chemotactic in these models of
breast cancer, it suggests that MT may play a role in breast cancer metastasis.

Messina 19

A

B

Figure 3. MT is Chemotactic in Mammary Tumor Cell Lines.
The bottom chamber was loaded with either 10µM MT or media alone. Boyden chamber was
assembled using an 8µm pore (A) or 3µm pore (B) membrane. 8µm pore membranes were
coated in 10µg/mL fibronectin at 4°C overnight prior to use. MDA-MB-231 (A) or 419 (B) cells
(2million cells/mL) were loaded into the top chamber with either 10µM MT or media alone.
Boyden Chamber was incubated for 6 hours (A) or 3 hours (B) at 37°C in 5% CO 2. Cells on the
underside of the membrane were enumerated using a light microscope under 10x. One-way
ANOVA followed by Tukey’s Multiple Comparisons Test was used to determine statistical
significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs
are representative of three independent experiments.
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MT Peptides and the Chemotactic Response in Mammary Tumor Cell Lines
Previous studies in the Lynes Lab have shown that pre-incubation with MT can block
SDF-1α-mediated chemotaxis in Jurkat T cells. This finding prompted the development of MT
peptides using the sequence of MT-1 (Table 1) to determine which region of MT binds to its
receptor(s) to initiate the chemotactic response. Experiments conducted using Jurkat T cells
indicated that the N-terminal region of MT interacts with its receptor 25. In the experiments
conducted in Figure 4, I used MT peptides to characterize MT’s interaction with its receptor in
breast cancer using 419 cells as a model of mammary tumorigenesis.
In Figure 4A, I used the Boyden Chamber assay to determine if MT peptides are
chemotactic in 419 cells. If any of the MT peptides are chemotactic, this would indicate that
those amino acids are responsible for interacting with MT’s receptor(s) on the cell surface to
initiate the chemotactic response. MT peptides, MT (MT control), or media alone (media
control) were loaded into the wells of the bottom chamber. Boyden Chamber was assembled, and
419 cells were loaded into the wells of the upper chamber. Results from this experiment showed
that none of the MT peptides caused an increase in cell migration compared to the Media control,
which suggests that they are not chemotactic on their own. While these results did not provide
any information as to which amino acids interact with MT’s receptor, they do suggest that there
is some important interaction between full-length MT and the receptor that shortened peptides
alone cannot establish.
In Figure 4B, I investigated the ability of MT peptides to block MT-mediated chemotaxis
in 419 cells. If any MT peptide occupies the binding site for MT on the receptor, it will inhibit
MT binding, thus blocking MT’s chemotactic effect. 419 cells were pre-incubated with MT
peptides, MT or media alone (MT control and Media control). The wells of the bottom chamber
Messina 21

were loaded with MT (MT peptides, MT, and MT Control) or media alone (Media control). The
Boyden Chamber was assembled, and the wells of the top chamber were loaded with 419 cells. I
found that pre-incubation with MT1-10, MT4-12, and MT11-20 results in a reduction in cell
migration compared to the MT control, suggesting that these peptides can block MT-mediated
chemotaxis.
In Figure 4C, I examined the ability of MT peptides to block Stromal Cell-Derived
Factor-1α (SDF-1α)-mediated chemotaxis in 419 cells. The design of this experiment was
similar to that of the experiment conducted in Figure 4B, however SDF-1α was used as the
chemoattractant instead of MT. Since it has been shown that MT can block SDF-1α-mediated
chemotaxis25, the ability of one (or more) of the MT peptides to block this response would
indicate that that region of MT is responsible for binding to MT’s receptor(s). 419 cells were preincubated with MT peptides, MT or media alone (SDF-1α control and Media control). The wells
of the bottom chamber were loaded with SDF-1α (MT peptides, MT, and SDF-1α Control) or
media alone (Media control). The Boyden Chamber was assembled, and the wells of the top
chamber were loaded with 419 cells. I found that pre-incubation with MT 1-10, MT4-12, and MT1120

results in a reduction in cell migration compared to the SDF-1α control, suggesting that these

peptides can block SDF-1α-mediated chemotaxis. These results are consistent with those found
in experiments using MT as the chemoattractant (Figure 4B).
While the MT peptides were not able to elicit a chemotactic response on their own, a few
of peptides corresponding with the N-terminus of the protein (MT 1-10, MT4-12, and MT11-20) were
able to block both MT-mediated and SDF-1α-mediated chemotaxis in 419 cells. Taken together,
the results from experiments conducted in Figure 4 suggest that there is some important
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interaction between full-length MT and its receptor that is necessary to illicit the chemotactic
response that MT peptides alone cannot establish, and that the N-terminus of MT is responsible
for binding to its receptor.
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A

B

C

Figure 4. MT Peptides and the Chemotactic Response in Mammary Tumor Cell Lines
(A) Chemoattractants (100µg/mL MT peptides, 100µg/mL MT or media alone) were loaded into
the bottom chamber. Boyden chamber was assembled using a 3µm pore membrane. 419 cells
(2million cells/mL) were loaded into the upper chamber. (B) 419 cells were pre-incubated for 1
hour with either 100µg/mL MT peptides, 100µg/mL MT or media alone (MT control and Media
control) at 37°C in 5% CO2. 10µM MT (MT peptides, MT, and MT control) or media alone
(Media control) was loaded into the bottom chamber. Boyden chamber was assembled using a
Messina 24

3µm pore membrane. Cells were washed, resuspended at 2million cells/mL, and loaded into the
upper chamber. (C) 419 cells were pre-incubated for 1 hour with either 100µg/mL MT peptides,
100µg/mL MT or media alone (SDF-1α control and Media control) at 37°C in 5% CO 2.
100ng/mL SDF-1α (MT peptides, MT, and SDF-1α control) or media alone (Media control) was
loaded into the bottom chamber. Boyden chamber was assembled using a 3µm pore membrane.
Cells were washed, resuspended at 2million cells/mL, and loaded into the upper chamber.
(A+B+C) Boyden chamber was incubated for 3 hours at 37°C in 5% CO 2. Cells on the underside
of the membrane were enumerated using a light microscope under 10x. Experimental conditions
were compared to the Media control (A), the MT control (B) or the SDF-1α control (C) and Oneway ANOVA followed by Tukey’s Multiple Comparisons Test was used to determine statistical
significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs
are representative of three independent experiments.

MT Interacts with CXCR4 to Initiate the Chemotactic Response in Mammary
Tumor Cell Lines
Previous studies in the Lynes Lab have shown that MT can interfere with SDF-1αCXCR4 mediated chemotaxis25. In addition, it has been shown that MT-mediated chemotaxis
can be blocked by Cholera toxin and Pertussis toxin, both of which are known antagonists of
GPCRs11. These findings suggested that MT interacts with CXCR4 to initiate the chemotactic
response.
AMD3100 (AnorMeD 3100), originally known as JM3100, is a small molecule inhibitor
of CXCR4 that was initially identified for its ability to target HIV viral protein gp120. Later
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studies found that AMD3100 blocked the interaction between gp120 and chemokine receptor
CXCR4, preventing the entry of HIV virus into the cell 37,38. Currently, AMD3100 is being
examined for its ability to act as an HIV entry inhibitor, to mobilize stem cells, and to treat
leukemias and solid tumors39.
AMD3100 has been shown to block MT-mediated chemotaxis in Jurkat T cells, which
suggests that CXCR4 plays a role in MT’s chemotactic response in lymphocytes and thus
inflammation associated with MT expression25. In these experiments, I will determine if
AMD3100 also blocks MT-mediated chemotaxis in mammary tumor cell models. If AMD3100
blocks MT-mediated chemotaxis in MDA-MB-231 cells and 419 cells, this would suggest that
CXCR4 is involved in MT’s chemotactic signaling pathways in breast cancer.
In Figure 5, MDA-MB-231 cells (Figure 5A) or 419 cells (Figure 5B) were pre-incubated
with non-toxic doses of AMD3100 (Figure S1). MT control and Media control cells were preincubated in media alone. MT (MT control and AMD3100) or media alone (Media control) was
loaded into the wells of the bottom chamber. The Boyden Chamber was assembled, and cells
were loaded into the wells of the upper chamber. Pre-incubation with AMD3100 results in a
statistically significant decrease in the average number of cells migrated per well in both MDAMB-231 cells (Figure 5A) and 419 cells (Figure 5B).
The fact that pre-incubation with AMD3100 blocks MT-mediated chemotaxis in
mammary tumor cell models suggests that CXCR4 is involved in MT’s chemotactic signaling
pathways. While CXCR4 may not be the only receptor that MT interacts with to initiate its
chemotactic response, these results provide valuable insight into MT’s mechanism of action as a
chemoattractant, which will help us understand how manipulating the extracellular pool of MT
may have therapeutic benefits in breast cancer.
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Figure 5. CXCR4 is Involved in MT-Mediated Chemotaxis in Mammary Tumor Cell Lines.
Cells were pre-incubated with AMD3100 for 30 minutes at 37°C in 5% CO 2. 20µg/mL
AMD3100 was used with MDA-MB-231 cells (A), while 10µg/mL AMD3100 was used with
419 cells (B) as determined by dose response and viability experiments (Fig. S1). Media and MT
controls were pre-incubated under the same conditions in media alone. The bottom chamber was
loaded with either 10µM MT (MT control and AMD3100) or media alone (Media control).
Boyden chamber was assembled using an 8µm (A) or 3µm pore (B) membrane. 8µm pore
membranes were coated in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed
in media, resuspended at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber
was incubated for 6 hours (A) or 3 hours (B) at 37°C in 5% CO2. Cells on the underside of the
membrane were enumerated using a light microscope under 10x. One-way ANOVA followed by
Tukey’s Multiple Comparisons Test was used to determine statistical significance with * = p ≤
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0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three
independent experiments.

The Arp2/3 Complex is Involved in MT-Mediated Chemotaxis
Actin Related Protein 2/3 (Arp2/3) complex plays an important role in the regulation of
the actin cytoskeleton by catalyzing actin filament nucleation. Arp2/3 bound to existing actin
filaments interacts with ATP and nucleation-promoting factors to facilitate the addition of actin
monomers to the filament40,41. As previously discussed, MT exposure results in an increase in Factin concentrations in cells11. This led to the hypothesis that the Arp2/3 complex is involved in
MT’s chemotactic signaling pathways.
CK-666, a small molecule inhibitor of the Arp2/3 complex, was used to test this
hypothesis. CK-666 inhibits the activity of the Arp2/3 complex by stabilizing the inactive state
of the complex. CK-666 blocks the movement of both the Arp2 and the Arp3 subunits into the
active conformation, thereby preventing the nucleation of actin filament 42.
First, I examined the role of the Arp2/3 complex in MT-mediated chemotaxis as it relates
to infiltration of immune cells and subsequent inflammation. For these experiments, I preincubated Jurkat T cells (Figure 6A) or primary mouse splenocytes (Figure 6B) with nontoxic
doses of CK-666 (Figure S2). MT control and Media control cells were pre-incubated in media
alone. MT (MT control and CK-666) or media alone (Media control) was loaded into the wells
of the bottom chamber. After the Boyden Chamber was assembled, cells were loaded into the
wells of the top chamber. Pre-incubation with CK-666 results in a statistically significant
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decrease in the average number of cells migrated per well in both Jurkat T cells (Figure 6A) and
primary mouse splenocytes (Figure 6B).
Next, I examined the role of the Arp2/3 complex in MT-mediated chemotaxis as it relates
to breast cancer metastasis. For these experiments, I pre-incubated MDA-MB-231 cells (Figure
6C) or 419 cells (Figure 6D) with nontoxic doses of CK-666 (Figure S2). MT control and Media
control cells were pre-incubated in media alone. MT (MT control and CK-666) or media alone
(Media control) was loaded into the wells of the bottom chamber. After the Boyden Chamber
was assembled, cells were loaded into the wells of the top chamber. Pre-incubation with CK-666
results in a statistically significant decrease in the average number of cells migrated per well in
both MDA-MB-231 cells (Figure 6C) and 419 cells (Figure 6D).
The fact that pre-incubation with CK-666 blocks MT-mediated chemotaxis in
lymphocytes and mammary tumor cell lines suggests that the Arp2/3 complex is involved in
MT’s chemotactic signaling pathways. This result is significant as it provides valuable insight
regarding the mechanism by which MT induces chemotaxis. By understanding MT’s mechanism
of action, we can identify the therapeutic opportunities of manipulating the extracellular pool of
MT to reduce inflammation and prevent breast cancer metastasis.
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Figure 6. Arp2/3 is Involved in MT-Mediated Chemotaxis.
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D)
were pre-incubated with 100µM CK-666 for 1 hour at 37°C in 5% CO 2 as determined by dose
response and viability experiments (Fig. S2). Media and MT controls were pre-incubated under
the same conditions in media alone. The bottom chamber was loaded with either 10µM MT (MT
control and CK-666) or media alone (Media control). Boyden chamber was assembled using an
8µm (C), 5µM (A), or 3µm pore (B+D) membrane. 8µm pore membranes were coated in
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10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours
(A+B+D) or 6 hours (C) at 37°C in 5% CO2. Cells on the underside of the membrane were
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** =
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three independent
experiments.

Phospholipase C is Involved in MT-Mediated Chemotaxis
Phospholipase C (PLC) β has been shown to be involved in G-protein coupled receptor
signaling pathways in T lymphocytes. GPCR subunit Gαi activates PLCβ and phosphoinositol-3kinase (PI3K) γ, which results in modification of the phospholipids produced by
phosphatidylinositol 4,5-bisphosphate (PIP2). Subsequently, the hydrolysis of PIP2 results in the
production of 1,4,5-triphosphate (IP3), which causes an increase in intracellular calcium. This
PLCβ signaling cascade has been shown to be involved in the chemotactic response initiated by
several different chemokines including SDF-1α43.
To investigate the role of PLC in MT-mediated chemotaxis, I used small molecule
inhibitor U73122. U73122 blocks PLC signaling by reducing the availability of PIP 2, a substrate
of the PLC signaling cascade44.
First, I conducted experiments using Jurkat T cells and primary mouse splenocytes to
determine the involvement of PLC in MT-mediated chemotaxis in the infiltration of immune
cells. Jurkat T cells (Figure 7A) and primary mouse splenocytes (Figure 7B) were pre-incubated
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with non-toxic doses of U73122 (Figure S3). MT control and Media control cells were preincubated in media alone. MT (MT control and U73122) or media alone (Media control) was
loaded into the wells of the bottom chamber. After the Boyden Chamber was assembled, cells
were loaded into the wells of the top chamber. Pre-incubation with U73122 results in a
statistically significant decrease in the average number of cells migrated per well in both Jurkat T
cells (Figure 7A) and primary mouse splenocytes (Figure 7B).
Next, I examined the role of PLC in MT-mediated chemotaxis as it relates to breast
cancer metastasis. For these experiments, I pre-incubated MDA-MB-231 cells (Figure 7C) and
419 cells (Figure 7D) with U73122 at non-toxic doses (Figure S3). MT control and Media
control cells were pre-incubated in media alone. MT (MT control and U73122) or media alone
(Media control) was loaded into the wells of the bottom chamber. Boyden chamber was
assembled, and cells were loaded into the wells of the top chamber. Pre-incubation experiments
showed that U73122 treatment results in a statistically significant decrease in the average
number of cells migrated per well in both MDA-MB-231 cells (Figure 7C) and 419 cells (Figure
7D).
Results from U73122 pre-incubation experiments indicate that U73122 can block MTmediated chemotaxis in both lymphocytes and mammary tumor cell lines, which suggests that
PLC is involved in MT’s chemotactic signaling pathways. These experiments have provided
valuable information regarding the mechanism by which MT elicits a chemotactic response. This
will allow us to more accurately understand the therapeutic potential of manipulating the
extracellular pool of MT in both inflammation and breast cancer.
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Figure 7. PLC is Involved in MT-Mediated Chemotaxis.
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D)
were pre-incubated with 1µM (A+B) or 5µM (C+D) U73122 for 30 minutes in at 37°C in 5%
CO2 as determined by dose response and viability experiments (Fig. S3). Media and MT controls
were pre-incubated under the same conditions in media alone. The bottom chamber was loaded
with either 10µM MT (MT control and U73122) or media alone (Media control). Boyden
chamber was assembled using an 8µm (C), 5µM (A), or 3µm pore (B+D) membrane. 8µm pore
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membranes were coated in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed
in media, resuspended at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber
was incubated for 3 hours (A+B+D) or 6 hours (C) at 37°C in 5% CO 2. Cells on the underside of
the membrane were enumerated using a light microscope under 10x. One-way ANOVA followed
by Tukey’s Multiple Comparisons Test was used to determine statistical significance with * = p
≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three
independent experiments.

MEK is Not Involved in MT-Mediated Chemotaxis
The mitogen activated protein kinase (MAPK) signaling pathway is involved in many
cellular processes including development, differentiation, and proliferation. Small G proteins
known as RAS can phosphorylate mitogen activated protein kinase kinase kinase (MAPKKK) to
activate it. MAPKK then activates MAPKK (MEK). Following their activation, MEKs can then
phosphorylate tyrosine and threonine residues on extracellular signaling regulated kinase (ERK)
to activate it45.
Previous studies conducted in the Lynes Lab have shown that MT can stimulate ERK1/2
activation, but that this activation only lasts a short amount of time (about two minutes) 25. These
results led to my interest in investigating the role of MEK in MT-mediated chemotaxis. To
examine MEK’s involvement in MT’s chemotactic signaling cascades, I used PD98059, a small
molecule inhibitor of MEK. PD98059 binds to the inactive form of MEK to prevent its activation
by upstream activators46.
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First, I conducted experiments using Jurkat T cells and primary mouse splenocytes to
determine the involvement of MEK in MT-mediated chemotaxis in the infiltration of immune
cells. Jurkat T cells (Figure 8A) and primary mouse splenocytes (Figure 8B) were pre-incubated
with non-toxic doses of PD98059 (Figure S4). MT control and Media control cells were preincubated in media alone. MT (MT control and PD98059) or media alone (Media control) was
loaded into the wells of the bottom chamber. After the Boyden Chamber was assembled, cells
were loaded into the wells of the top chamber. These results show that pre-incubation with
PD98059 has no effect on the average number of cells migrated per well in both Jurkat T cells
(Figure 8A) and primary mouse splenocytes (Figure 8B).
Next, I used mammary tumor cell lines to determine if MEK is involved in MT-mediated
chemotaxis in breast cancer. MDA-MB-231 cells (Figure 8C) and 419 cells (Figure 8D) were
pre-incubated with non-toxic doses of PD98059 (Figure S4). MT control and Media control cells
were pre-incubated in media alone. MT (MT control and PD98059) or media alone (Media
control) was loaded into the wells of the bottom chamber. After the Boyden Chamber was
assembled, cells were loaded into the wells of the top chamber. These results show that preincubation with PD98059 has no effect on the average number of cells migrated per well in both
MDA-MB-231 cells (Figure 8C) and primary mouse splenocytes (Figure 8D).
Results from PD98059 experiments show that pre-incubation with this small molecule
inhibitor does not block MT-mediated chemotaxis in both immune cells and mammary tumor
cells lines, which suggests that MEK is not involved in MT’s chemotactic signaling pathways.
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Figure 8. MEK is Not Involved in MT-Mediated Chemotaxis.
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D)
were pre-incubated with 50µM, 20µM, or 1µM PD98059 for 1 hour at 37°C in 5% CO 2.
PD98059 concentrations were determined to be non-toxic in viability experiments (Fig. S4).
Media and MT controls were pre-incubated under the same conditions in media alone. The
bottom chamber was loaded with either 10µM MT (MT control and PD98059) or media alone
(Media control). Boyden chamber was assembled using an 8µm (C), 5µM (A), or 3µm pore
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(B+D) membrane. 8µm pore membranes were coated in 10µg/mL fibronectin at 4°C overnight
prior to use. Cells were washed in media, resuspended at 2 million cells/mL, and loaded into the
top chamber. Boyden Chamber was incubated for 3 hours (A+B+D) or 6 hours (C) at 37°C in
5% CO2. Cells on the underside of the membrane were enumerated using a light microscope
under 10x. One-way ANOVA followed by Tukey’s Multiple Comparisons Test was used to
determine statistical significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p
≤ 0.0001. Graphs are representative of three independent experiments.

UC1MT Blocks MT-Mediated Chemotaxis in Breast Cancer Cell Models
UC1MT, a monoclonal anti-MT antibody, has been shown to alter the
immunomodulatory effects of MT in immune cells 12,13. Previous studies in the Lynes lab have
shown that UC1MT can block MT-mediated chemotaxis in both Jurkat T cells and primary
mouse splenocytes11,25. These results suggested that UC1MT may have therapeutic benefits in
inflammatory diseases. A subsequent study conducting in a DSS-induced mouse model of colitis
showed that UC1MT can reduce immune cell infiltration and inflammation in the gut, indicating
that it may be a useful therapeutic to treat inflammatory bowel diseases 22. Additionally, a study
conducted in female NOD mice, which serve as a murine model of Type 1 Diabetes showed that
treatment with UC1MT can prevent the development of Type 1 Diabetes 25. While UC1MT has
shown great promise in the treatment in inflammatory diseases, it has not yet been evaluated in
breast cancer models. Here, I will examine the ability of UC1MT to block MT-mediated
chemotaxis in mammary tumor cell lines.
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For these experiments, I pre-incubated media, MT, and SDF-1α with UC1MT. Then, I
loaded the wells of the bottom chamber with either media, MT, or SDF-1α with and without
UC1MT pre-incubation. After assembly of the Boyden chamber, MDA-MB-231 cells (Figure
9A) or 419 cells (Figure 9B) were loaded into the wells of the upper chamber. These results
show that MT pre-incubation with UC1MT results in a decrease in the average number of cells
migrated per well in both MDA-MB-231 cells (Figure 9A) and 419 cells (Figure 9B), but that
media or SDF-1α pre-incubation with MT does not result in this effect.
The reduction in cell migration seen when MT is pre-incubated with UC1MT suggests
that UC1MT blocks MT-mediated chemotaxis in mammary tumor cell lines. The fact that SDF1α pre-incubation with UC1MT does not result in a reduction in the chemotactic response
suggests that UC1MT specifically binds to MT to block its chemotactic response. Because
UC1MT can block MT-mediated chemotaxis in mammary tumor cell lines, it may serve as a
useful therapeutic to inhibit breast cancer metastasis.
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A

B

Figure 9. UC1MT Blocks MT-Mediated Chemotaxis in Breast Cancer Cell Models.
Chemoattractants were pre-incubated with 50µg/mL UC1MT or in media alone for 1 hour at
room temperature and then loaded into the bottom chamber. Boyden chamber was assembled
using an 8µm pore (A) or 3µm pore (B) membrane. 8µm pore membranes were coated in
10µg/mL fibronectin at 4°C overnight prior to use. MDA-MB-231 (A) or 419 (B) cells (2million
cells/mL) were loaded into the top chamber. Boyden Chamber was incubated for 6 hours (A) or
3 hours (B) at 37°C in 5% CO2. Cells on the underside of the membrane were enumerated using
a light microscope under 10x. One-way ANOVA followed by Tukey’s Multiple Comparisons
Test was used to determine statistical significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤
0.001, and **** = p ≤ 0.0001. Graphs are representative of three independent experiments.
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Discussion
MT expression has been linked to inflammation and many disease phenotypes including
IBD, diabetes, and many types of cancer15,16,20. Previous studies in the Lynes Lab have shown
that MT acts as a chemoattractant in lymphocytes and that MT-mediated chemotaxis can be
blocked by UC1MT, a monoclonal anti-MT antibody11,25. It has also been shown that GPCR
antagonists Cholera toxin and Pertussis toxin can block MT’s chemotactic effect 11, which
suggests that MT may interact with a GPCR to initiate its chemotactic signaling cascades. Here, I
have investigated the mechanism by which MT initiates a chemotactic response in both
inflammation and breast cancer.
Breast cancer is the second leading cause of death in women in the United States, with
one in eight women developing the disease in her lifetime 31. Elevated MT expression has been
linked to inflammation and poor prognosis in patients with breast cancer 32–36. MT’s association
with breast cancer led to the interest in examining the chemotactic potential of MT in breast
cancer cell models. In these experiments, MDA-MB-231 cells (Figure 3A) and 419 cells (Figure
3B) served as cell models for breast cancer. Results from these experiments showed that MT acts
as a chemoattractant in mammary tumor cell lines, which suggests that MT may play a role in
breast cancer metastasis. This finding prompted exploration of the mechanism by which MT
initiates the chemotactic response and if UC1MT would block MT-mediated chemotaxis in
breast cancer cell models.
Next, MT peptides were used to determine which region of full-length MT interacts with
a receptor on the surface of cells to initiate its chemotactic signaling pathways. Previous studies
in the Lynes Lab examined the ability of MT peptides to block SDF-1α-mediated chemotaxis in
Jurkat T cells. These studies suggested that the N-terminus of MT is responsible for MT’s
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binding to its receptor(s)25. While these results indicate that the N-terminus of MT binds to its
receptor(s) in lymphocytes, it had not yet been explored if the same was true in mammary tumor
cell lines. For these experiments, I used 419 cells as a model for mammary tumorigenesis. It was
found that MT peptides are not chemotactic on their own, but that MT 1-10, MT4-12, and MT11-20
can block both MT and SDF-1α-mediated chemotaxis in breast cancer cell models. These results
suggest that the N-terminus of MT is responsible for binding to its receptor(s) and are consistent
with the results of experiments conducted in lymphocytes.
AMD3100, a small molecule inhibitor of receptor CXCR4, was used to determine the
involvement of CXCR4 in MT’s chemotactic signaling in mammary tumor cell lines. Studies
conducted in Jurkat T cells found that MT can block SDF-1α-CXCR4 mediated chemotaxis.
Subsequently, AMD3100 was used to determine the involvement of CXCR4 in MT-mediated
chemotaxis in lymphocytes. It was found that AMD3100 can block MT-mediated chemotaxis in
lymphocytes, which suggests that MT interacts with CXCR4 to initiate its chemotactic
response25. Similarly, experiments conducted in mammary tumor cell lines show that AMD3100
blocks MT-mediated chemotaxis (Figure 5). This suggests that CXCR4 is involved in the
initiation of MT’s signaling cascades in both lymphocytes and breast cancer cell models.
MT exposure has been shown to increase F-actin levels in lymphoctyes 11, which suggests
the involvement of the Arp2/3 complex the signaling pathways of MT-mediated chemotaxis.
Small molecule inhibitor CK-666 was used to evaluate the involvement of the Arp2/3 complex in
MT-mediated chemotaxis in both lymphocytes and mammary tumor cell lines. CK-666 preincubation blocks MT-mediated chemotaxis immune cells (Figure 6 A+B) and mammary tumor
cells (Figure 6 C+D), which suggests that the Arp2/3 complex is involved in MT’s chemotactic
signaling pathways.
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PLCβ signaling results in an increase in intracellular calcium levels and is known to be
involved in SDF-1α-CXCR4 mediated chemotaxis43. U73122, a small molecule inhibitor of
PLC, was used to examine the role of PLC in MT-mediated chemotaxis. These experiments
showed that pre-incubation with U73122 blocks the chemotactic response in both lymphocytes
(Figure 7 A+B) and breast cancer cell models (Figure 7 C+D). These results suggest that PLC
signaling is involved in the initiation of MT’s chemotactic response.
MEK signaling cascades are involved in many important cellular processes including
differentiation and proliferation45. While previous studies in the Lynes Lab have shown that MT
exposure results in short term activation of ERK1/225, the role of this pathway in MT’s
chemotactic response was not known. PD98059, a small molecule inhibitor of MEK, was used to
determine the involvement of MEK signaling in MT-mediated chemotaxis. Pre-incubation with
PD98059 did not block MT’s chemotactic response in both lymphocytes (Figure 8 A+B) and
mammary tumor cell lines (Figure 8 C+D). These results indicate that MEK is likely not
involved in MT’s chemotactic signaling pathways.
Finally, the ability of UC1MT to block MT-mediated chemotaxis in mammary tumor cell
lines was examined. Previous studies showed that pre-incubation with UC1MT blocks MTmediated chemotaxis in lymphocytes, and that it has therapeutic potential in the treatment of IBD
and diabetes11,22,25. However, the potential of using UC1MT as a therapeutic for breast cancer
had not yet been evaluated. Results here show that pre-incubation with UC1MT specifically
blocks MT-mediated chemotaxis in mammary tumor cell lines (Figure 9). This suggests that
UC1MT may be a valuable therapeutic to inhibit breast cancer metastasis.
Taking the results from all these experiments into account, I have proposed a model for
the signaling pathways involved in MT-mediated chemotaxis (Figure 10). I propose that
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exogenous MT interacts with CXCR4 (or other unknown receptors) on the surface of the cell.
This binding event results in the dissociation of Gα and Gβγ. Currently, the role of Gα in MTmediated chemotaxis is unknown. Gβγ activates signaling cascades involving PLC and the
Arp2/3 complex, which results in a chemotactic response. It is of note that G βγ may initiate
additional pathways to result in chemotaxis, however we have not explored these possibilities.
While MEK signaling is known to have important functions in the cell, it is not involved in MT’s
chemotactic signaling pathways. Finally, UC1MT can bind to exogenous MT to block MT’s
interaction with its receptor and prevent the chemotactic response.
These results have provided valuable information regarding the mechanism by which MT
initiates a chemotactic response, which allows us to further understand MT’s role in
inflammation and disease processes, and will help us identify other therapeutic targets for
UC1MT in the future. Furthermore, the fact that UC1MT blocks MT-mediated chemotaxis in
mammary tumor cell lines suggests that UC1MT may inhibit breast cancer metastasis.
Next steps for this project include investigating the role of other chemokine receptors,
such as CXCR7, and the role of other common GPCR signaling cascades in MT-mediated
chemotaxis. Most importantly, animal studies, likely in a mouse model, must be conducted to
determine if UC1MT can inhibit mammary tumorigenesis and metastasis to improve patient
outcomes.
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Figure 10. Proposed Signaling Pathway of MT-mediated Chemotaxis
Exogenous MT interacts with chemokine receptor CXCR4. The binding of MT to CXCR4
results in the dissociation of Gα and Gβγ. The role of Gα in MT-mediated chemotaxis is currently
unknown. Results from these experiments suggest that G βγ initiates downstream signaling
cascades, which result in the activation of both the Arp2/3 complex and phospholipase C (PLC).
The activation of these complexes initiates cytoskeletal reorganization, which leads to the
chemotactic response. It is currently unknown if G βγ activates other downstream signaling
pathways to initiate MT’s chemotactic response. UC1MT can bind to MT to block its interaction
with CXCR4 (or other unknown receptors) and inhibit MT’s chemotactic effect. MEK signaling
does not appear to play a role in MT-mediated chemotaxis.
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Supplemental Figures

A

B

C

D

Figure S1. Dose Response and Cell Viability with AMD3100 Pre-incubation
MDA-MB-231(A+B) or 419 (C+D) cells were pre-incubated with various concentrations of
AMD3100 for 30 minutes at 37°C in 5% CO2. Media and MT controls were pre-incubated under
the same conditions in media alone. After pre-incubation, cell viability (B+D) was calculated
using a hemocytometer and trypan blue exclusion staining. The bottom chamber was loaded with
either 10µM MT (MT control and AMD3100) or media alone (Media control). Boyden chamber
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was assembled using an 8µm (A) or 3µm pore (C) membrane. 8µm pore membranes were coated
in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended
at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 6
hours (A) or 3 hours (C) at 37°C in 5% CO2. Cells on the underside of the membrane were
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** =
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001.
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Figure S2. Dose Response and Cell Viability with CK-666 Pre-incubation
Jurkat T cells (A+B), Primary Mouse Splenocytes (C+D), MDA-MB-231 cells (E+F), or 419
cells (G+H) were pre-incubated with various concentrations of CK-666 for 1 hour at 37°C in 5%
CO2. Media and MT controls were pre-incubated under the same conditions in media alone. The
bottom chamber was loaded with either 10µM MT (MT control and CK-666) or media alone
(Media control). After pre-incubation, cell viability (B+D+F+H) was calculated using a
hemocytometer and trypan blue exclusion staining. Boyden chamber was assembled using an
8µm (E), 5µM (A), or 3µm pore (C+G) membrane. 8µm pore membranes were coated in
10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours
(A+C+G) or 6 hours (E) at 37°C in 5% CO2. Cells on the underside of the membrane were
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** =
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001.
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Figure S3. Dose Response and Cell Viability with U73122 Pre-incubation
Jurkat T cells (A+B), Primary Mouse Splenocytes (C+D), MDA-MB-231 cells (E+F) or 419
cells (G+H) were pre-incubated with various concentrations of U73122 for 30 minutes at 37°C in
5% CO2. Media and MT controls were pre-incubated under the same conditions in media alone.
After pre-incubation, cell viability (B+D+F+H) was calculated using a hemocytometer and
trypan blue exclusion staining. The bottom chamber was loaded with either 10µM MT (MT
control and U73122) or media alone (Media control). Boyden chamber was assembled using an
8µm (E), 5µM (A), or 3µm pore (C+G) membrane. 8µm pore membranes were coated in
10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours
(A+C+G) or 6 hours (E) at 37°C in 5% CO2. Cells on the underside of the membrane were
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** =
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001.
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Figure S4. Cell Viability with PD98059 Pre-incubation
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D)
were pre-incubated with various concentrations of PD98059 for 1 hour at 37°C in 5% CO 2.
Media and MT controls were pre-incubated under the same conditions in media alone. After preincubation, cell viability was calculated using a hemocytometer and trypan blue exclusion
staining.
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